Sedative, Amnestic, and Analgesic Properties of Small-Dose Dexmedetomidine Infusions

By J. Hall, T. Uhrich, J. A. Barney, S. R. Arain, T. Ebert. Anesthesia and Analgesia, 2000

1,208 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Descending control of pain. (2002, background): “These actions reflect the engagement of DH-localised 2-ARs and are most convincingly expressed upon spinal (epidural or intrathecal) administration (Eisenach, 1994; Eisenach et al., 1995a, 1996, 1998, 2000; Glynn and O’Sullivan, 1995; Curatolo et al., 1997; De Kock et al., 1997; Millan, 1997; D’Ange”
Clinical Uses of ??2-Adrenergic Agonists: (2000, background): “Patients who were administered dexmedetomidine required significantly less propofol than did placebotreated patients for the same level of clinical sedation; qualitatively, a unique type of sedation was produced in which patients could be aroused readily and then returned to a sleep-like state when ”
Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine (2017, background): “An important feature of dexmedetomidine-based sedation is that patients remain easily rousable [6].”
Dexmedetomidine: A Novel Sedative-Analgesic Agent (2001, background): “All values were reduced by dexmedetomidine but had returned to baseline 4 hours after treatment (17).”